For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

31st Mar 21

Pharmaxis Announces World First Clinical Trial of Treatment to Prevent Wound and Burns Scars

A Pharmaxis (ASX:PXS) drug discovery has entered a world first clinical trial aiming to stop scars forming after trauma, particularly following burn injuries. Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials. Skin scarring after events such as accidents, surgery or burns place a substantial physical and psychological burden on patients. 

Professor Fiona Wood said, “It’s exciting for the research team to explore a novel path to reduce scarring and to be moving closer to that goal. Scar-less healing is the vision that has motivated our work over many decades.”

The Pharmaxis discovery, known as PXS-6302, has shown promising pre-clinical results in inhibiting the enzymes that play a critical role in the development of scar tissue.

Dr Kylie Sandy-Hodgetts, Senior Research Fellow at the School of Biomedical Sciences, UWA, said, “Current treatments aim to rectify the scar in the acute phase such as during wound healing and scar maturation through options such as compression therapy, silicone gel sheeting or when the scar is established by cryotherapy, scar revision or laser with limited outcomes at times.”

“This new compound may potentially avoid the need for invasive procedures such as further surgery or laser procedures.”

 The world-first human trial will determine the safety and tolerability of the product in healthy volunteers, which will lead to further trials in burns and surgical patients.

Read full media release - pdf
19th Mar 21

Chiesi USA Announces Commercial Launch of Pharmaxis’ Cystic Fibrosis Drug Bronchitol

Pharmaxis Ltd (ASX: PXS) today announced that Chiesi USA, Inc. (Chiesi), has launched Bronchitol® (mannitol), an add-on maintenance therapy to improve pulmonary function in cystic fibrosis (CF) patients aged 18 years and older in the United States. Bronchitol, developed by Pharmaxis, is the first dry powder inhaled mucoactive agent providing a compact, portable treatment option for CF patients.

Additionally, Chiesi has announced data from the Pharmaxis Phase 3 global clinical trial (CF303) evaluating the efficacy and safety of Bronchitol in adults with CF has been published online in the Journal of Cystic Fibrosis.

Pharmaxis has so far received a total of US$10 million in Bronchitol milestone payments from Chiesi triggered by FDA approval in October 2020 and the recent first shipment of stock to the USA.

Read full media release - pdf